Neoadjuvant Therapy for MIBC in the Genomic Era

For cutting-edge learning on bladder cancer, consider signing up for our International Bladder Cancer Update conference: https://grandroundsinurology.com/ibcu/

Colin P.N. Dinney, MD, Chairman of the Department of Urology in the Division of Surgery and Co-chair of the Genitourinary Steering Committee for the Bladder Task Force at the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in the genomic era. Dr. Dinney explains how the field is undergoing a paradigm shift in the management of MIBC, with practitioners moving away from a one-size-fits-all approach. Instead, practitioners will rely on tumor biology to guide the selection of patients for NAC, radical cystectomy alone, or bladder preservation.